4D pharma plc: 4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022

4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today reported financial

Related Keywords

Germany ,United States ,Kenilworth ,Warwickshire ,United Kingdom ,Ireland ,American ,Julie Seidel ,Neil Hunter Michelle Boxall ,Duncan Peyton ,Dominic Wilson ,Lynne Dardanell ,John Beck ,Philip Davies James Fischer ,Bryan Garnier Co ,Image Box Communications ,Nasdaq ,Development Milestones ,Merck Co Inc ,Development Expenses ,Merck Kga ,United States Securities Exchange ,Pfizer Inc ,Longevity Acquisition Corporation ,Drug Administration ,Exchange Commission ,Merck Kgaa ,Oxford Finance ,European Society For Medical Oncology ,University Marburg ,American Thoracic Society ,Chief Executive Officer ,Administrative Expense ,European Society ,Medical Oncology ,Digestive Disease Week ,Philipps University Marburg ,Paul Maier ,Non Executive Director ,Chief Financial Officer ,Events Since ,John Doyle ,Key Objectives ,Renal Cell Carcinoma ,United States Securities Act ,United States Securities Exchange Act ,Capital Markets Nominated Adviser ,Joint Broker ,Davies James Fischer ,Corporate Finance ,Corporate Broking ,Hunter Michelle Boxall ,Pharma ,Reports ,Bull ,Ear ,021 ,Financial ,Results ,Perational ,Highlights ,Guidance ,Ilestones ,022 ,